OncoMatch/Clinical Trials/NCT05123807
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
Is NCT05123807 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for ovarian cancer.
The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: hipec
Cannot have received: intraperitoneal chemotherapy
Lab requirements
Blood counts
absolute neutrophil count >1,500/mcL; platelets >100,000/mcL
Kidney function
creatinine ≤ 1.5 mg/dL
Liver function
total bilirubin ≤ 1.5 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal
absolute neutrophil count >1,500/mcL; platelets >100,000/mcL; total bilirubin ≤ 1.5 mg/dL; creatinine ≤ 1.5 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05123807 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hipec, intraperitoneal chemotherapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages